Zdrowie i gospodarka · 13/03/2009

FDA to Host Public Workshop on Defining Clinical Trial Endpoints for Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

The US Food and Drug Administration (FDA) will host a public workshop to discuss and establish clinical trial endpoints for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT), a common treatment for certain blood cancers.